Engineered Microbial Cells for Oxalate Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing elevated oxalate levels in the body, which can lead to conditions like hyperoxaluria and kidney stones, are not always effective and often require intensive treatments such as dialysis or organ transplantation.
Innovation Solution
Engineered microbial cells, such as probiotic bacteria or fungi, are designed to express oxalate catabolism genes, enabling them to metabolize oxalate and reduce its levels by converting it into non-toxic molecules like formate, thereby treating disorders associated with hyperoxaluria and kidney stones.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intensive treatments such as dialysis or organ transplantation are used to manage elevated oxalate levels, then the therapeutic effectiveness is improved, but the treatment complexity and invasiveness increase
Solution Approach 1:
The patent introduces engineered microbial cells as intermediary agents that perform oxalate degradation in the gut. These probiotic bacteria serve as a mediator between the host and the harmful oxalate, converting it into benign products without requiring invasive medical interventions. The microbial cells act as a biological intermediary that simplifies the treatment approach while maintaining effectiveness.
Solution Approach 2:
The engineered microbial cells utilize the host's own gut environment and microbiome to perform the therapeutic function. By leveraging the existing intestinal flora and metabolic pathways, the system achieves self-service oxalate degradation without external medical equipment or complex treatment protocols. The probiotics self-replicate and sustain their oxalate-degrading activity within the host's digestive system.
2Quantity of substance
If existing therapies such as high-dose pyridoxine, orthophosphate, magnesium, and dietary adjustments are used, then oxalate levels can be reduced, but the treatment effectiveness is insufficient for severe cases
Solution Approach 1:
The patent fundamentally changes the parameter of oxalate metabolism by introducing engineered microbial cells with enhanced oxalate catabolic capabilities. These probiotics possess modified metabolic pathways and enzymes that dramatically increase oxalate degradation efficiency compared to conventional therapies. The microbial cells can process large quantities of oxalate simultaneously, providing reliable and potent treatment for severe hyperoxaluria.
Solution Approach 2:
The engineered microbial cells function as composite biological systems that integrate multiple metabolic functions. Each probiotic strain combines oxalate transporters, catabolic enzymes, and regulatory mechanisms into a coordinated system that efficiently degrades oxalate. This composite biological approach provides superior and more reliable oxalate reduction compared to single-agent pharmaceuticals or dietary modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered microbial cells safely and effectively reduce oxalate levels in the body, providing a therapeutic option that is potentially less invasive than existing treatments, by augmenting the innate microbiome activities to prevent or treat conditions like hyperoxalurias and nephrolithiasis.
Implementation Method 1
The engineered microbial cells can be used to convert excess oxalate and/or oxalic acid into non-toxic molecules
Implementation Method 2
designed to express oxalate catabolism genes, enabling them to metabolize oxalate and reduce its levels by converting it into non-toxic molecules
Data Source
AI summary
The present disclosure relates to engineered microbial cells that have been engineered to comprise one or more oxalate catabolismgenes that are expressed under the control of non-native, non-inducible promoters. Thus, the genetically engineered microbial cells and pharmaceutical compositions comprising the microbial cells are useful in degrading oxalate inside or outside the engineered microbial cell, resulting in a reduction of the concentration of oxalate outside the cell. The engineered microbial cells of the present disclosure are useful in methods of treating or preventing diseases associated with disorders in which oxalate is detrimental, such as hyperoxalurias. The engineered microbial cells of the present disclosure are also useful in methods of treating calcium oxalate nephrocalcinosis, calcium oxalate nephrolithiasis and calcium oxalate urolithiasis.